67
Participants
Start Date
August 31, 2008
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2014
Palifosfamide Tris and Doxorubicin
On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Doxorubicin
On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
Coeur d'Alene
Cluj-Napoca
Santa Monica
Washington D.C.
Tampa
Chicago
Park Ridge
Iowa City
Lenaxa
Albuquerque
New York
Durham
Portland
Philadelphia
Memphis
Nashville
San Antonio
Salt Lake City
Seattle
Milan
Padua
Torino
Lasi
Lead Sponsor
Alaunos Therapeutics
INDUSTRY